HEADER TRANSFERASE 16-NOV-07 3BE9 TITLE STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[1, TITLE 2 5-A] [1,3,5]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE TITLE 3 CK2 AND THEIR ANTICANCER ACTIVITIES COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II, CK2-ALPHA; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: ZEA MAYS; SOURCE 3 ORGANISM_COMMON: MAIZE; SOURCE 4 ORGANISM_TAXID: 4577; SOURCE 5 GENE: ACK2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET-28A KEYWDS STRUCTURE-BASED DRUG DESIGN, ENZYME-INHIBITOR COMPLEX, CASEIN KINASE KEYWDS 2 II, PROTEIN KINASE CK2, ATP-BINDING, NUCLEOTIDE-BINDING, KEYWDS 3 SERINE/THREONINE-PROTEIN KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR Z.NIE,C.PERRETTA,P.ERICKSON,S.MARGOSIAK,J.LU,A.AVERILL,R.ALMASSY, AUTHOR 2 S.CHU REVDAT 5 30-AUG-23 3BE9 1 REMARK REVDAT 4 20-OCT-21 3BE9 1 REMARK SEQADV LINK REVDAT 3 04-APR-18 3BE9 1 REMARK REVDAT 2 24-FEB-09 3BE9 1 VERSN REVDAT 1 18-NOV-08 3BE9 0 JRNL AUTH Z.NIE,C.PERRETTA,P.ERICKSON,S.MARGOSIAK,J.LU,A.AVERILL, JRNL AUTH 2 R.ALMASSY,S.CHU JRNL TITL STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC JRNL TITL 2 PYRAZOLO[1,5-A] [1,3,5]TRIAZINE COMPOUNDS AS POTENT JRNL TITL 3 INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER JRNL TITL 4 ACTIVITIES. JRNL REF BIOORG.MED.CHEM.LETT. V. 18 619 2008 JRNL REFN ISSN 0960-894X JRNL PMID 18055206 JRNL DOI 10.1016/J.BMCL.2007.11.074 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 32.70 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 91.6 REMARK 3 NUMBER OF REFLECTIONS : 22890 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.190 REMARK 3 R VALUE (WORKING SET) : 0.190 REMARK 3 FREE R VALUE : 0.228 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 2284 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 23749 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.07 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 78.40 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1770 REMARK 3 BIN R VALUE (WORKING SET) : 0.2690 REMARK 3 BIN FREE R VALUE : 0.3340 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 191 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2734 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 27 REMARK 3 SOLVENT ATOMS : 246 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 26.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 5.09000 REMARK 3 B22 (A**2) : -3.12000 REMARK 3 B33 (A**2) : -1.97000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 1.68300 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.23 REMARK 3 ESD FROM SIGMAA (A) : 0.21 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.28 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.27 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.910 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 20.96 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.710 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.250 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.880 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.020 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.900 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : MASK REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3BE9 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 20-NOV-07. REMARK 100 THE DEPOSITION ID IS D_1000045410. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 21-DEC-05 REMARK 200 TEMPERATURE (KELVIN) : 112.0 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : ENRAF-NONIUS FR591 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54178 REMARK 200 MONOCHROMATOR : OSMIC CONFOCAL MAX-FLUX MIRRORS REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MAR SCANNER 345 MM PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 23749 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 32.700 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.0 REMARK 200 DATA REDUNDANCY : 3.540 REMARK 200 R MERGE (I) : 0.08400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 92.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.40900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNX REMARK 200 STARTING MODEL: PDB ENTRY 2PVJ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 45.24 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.25 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 14% PEG 4000, 0.05M SODIUM ACETATE, REMARK 280 0.10M TRISHCL, PH 8.0, VAPOR DIFFUSION, HANGING DROP, REMARK 280 TEMPERATURE 297K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 71.66350 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.78900 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 71.66350 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 29.78900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH A 734 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -14 REMARK 465 GLY A -13 REMARK 465 SER A -12 REMARK 465 SER A -11 REMARK 465 HIS A -10 REMARK 465 HIS A -9 REMARK 465 HIS A -8 REMARK 465 HIS A -7 REMARK 465 HIS A -6 REMARK 465 HIS A -5 REMARK 465 SER A -4 REMARK 465 SER A -3 REMARK 465 GLY A -2 REMARK 465 LEU A -1 REMARK 465 VAL A 0 REMARK 465 PRO A 1 REMARK 465 ARG A 2 REMARK 465 GLY A 3 REMARK 465 SER A 4 REMARK 465 HIS A 5 REMARK 465 ARG A 334 REMARK 465 THR A 335 REMARK 465 ARG A 336 REMARK 465 ALA A 337 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 12 28.09 49.60 REMARK 500 ASP A 120 120.32 -39.22 REMARK 500 ASP A 156 40.36 -155.99 REMARK 500 ASP A 175 86.96 50.97 REMARK 500 ALA A 193 -179.04 62.86 REMARK 500 TYR A 196 -25.93 88.88 REMARK 500 ASP A 210 -158.29 -147.57 REMARK 500 HIS A 236 -89.36 -92.02 REMARK 500 ALA A 287 -17.17 -48.47 REMARK 500 VAL A 293 48.57 -90.67 REMARK 500 ASN A 332 36.02 -74.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE P04 A 501 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2PVH RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE REMARK 900 RELATED ID: 2PVJ RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE REMARK 900 RELATED ID: 2PVK RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE REMARK 900 RELATED ID: 2PVL RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE REMARK 900 RELATED ID: 2PVM RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE REMARK 900 RELATED ID: 2PVN RELATED DB: PDB REMARK 900 SAME PROTEIN COMPLEXED WITH AN ACYCLIC PYRAZOLO[1,5-A][1,3,5] REMARK 900 TRIAZINE DERIVATIVE DBREF 3BE9 A 6 337 UNP P28523 CSK2A_MAIZE 1 332 SEQADV 3BE9 MET A -14 UNP P28523 EXPRESSION TAG SEQADV 3BE9 GLY A -13 UNP P28523 EXPRESSION TAG SEQADV 3BE9 SER A -12 UNP P28523 EXPRESSION TAG SEQADV 3BE9 SER A -11 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -10 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -9 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -8 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -7 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -6 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A -5 UNP P28523 EXPRESSION TAG SEQADV 3BE9 SER A -4 UNP P28523 EXPRESSION TAG SEQADV 3BE9 SER A -3 UNP P28523 EXPRESSION TAG SEQADV 3BE9 GLY A -2 UNP P28523 EXPRESSION TAG SEQADV 3BE9 LEU A -1 UNP P28523 EXPRESSION TAG SEQADV 3BE9 VAL A 0 UNP P28523 EXPRESSION TAG SEQADV 3BE9 PRO A 1 UNP P28523 EXPRESSION TAG SEQADV 3BE9 ARG A 2 UNP P28523 EXPRESSION TAG SEQADV 3BE9 GLY A 3 UNP P28523 EXPRESSION TAG SEQADV 3BE9 SER A 4 UNP P28523 EXPRESSION TAG SEQADV 3BE9 HIS A 5 UNP P28523 EXPRESSION TAG SEQADV 3BE9 ALA A 256 UNP P28523 VAL 251 ENGINEERED MUTATION SEQRES 1 A 352 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 A 352 LEU VAL PRO ARG GLY SER HIS MET SER LYS ALA ARG VAL SEQRES 3 A 352 TYR ALA ASP VAL ASN VAL LEU ARG PRO LYS GLU TYR TRP SEQRES 4 A 352 ASP TYR GLU ALA LEU THR VAL GLN TRP GLY GLU GLN ASP SEQRES 5 A 352 ASP TYR GLU VAL VAL ARG LYS VAL GLY ARG GLY LYS TYR SEQRES 6 A 352 SER GLU VAL PHE GLU GLY ILE ASN VAL ASN ASN ASN GLU SEQRES 7 A 352 LYS CYS ILE ILE LYS ILE LEU LYS PRO VAL LYS LYS LYS SEQRES 8 A 352 LYS ILE LYS ARG GLU ILE LYS ILE LEU GLN ASN LEU CSO SEQRES 9 A 352 GLY GLY PRO ASN ILE VAL LYS LEU LEU ASP ILE VAL ARG SEQRES 10 A 352 ASP GLN HIS SER LYS THR PRO SER LEU ILE PHE GLU TYR SEQRES 11 A 352 VAL ASN ASN THR ASP PHE LYS VAL LEU TYR PRO THR LEU SEQRES 12 A 352 THR ASP TYR ASP ILE ARG TYR TYR ILE TYR GLU LEU LEU SEQRES 13 A 352 LYS ALA LEU ASP TYR CYS HIS SER GLN GLY ILE MET HIS SEQRES 14 A 352 ARG ASP VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLU SEQRES 15 A 352 LEU ARG LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU SEQRES 16 A 352 PHE TYR HIS PRO GLY LYS GLU TYR ASN VAL ARG VAL ALA SEQRES 17 A 352 SER ARG TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP LEU SEQRES 18 A 352 GLN ASP TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY SEQRES 19 A 352 CYS MET PHE ALA GLY MET ILE PHE ARG LYS GLU PRO PHE SEQRES 20 A 352 PHE TYR GLY HIS ASP ASN HIS ASP GLN LEU VAL LYS ILE SEQRES 21 A 352 ALA LYS VAL LEU GLY THR ASP GLY LEU ASN ALA TYR LEU SEQRES 22 A 352 ASN LYS TYR ARG ILE GLU LEU ASP PRO GLN LEU GLU ALA SEQRES 23 A 352 LEU VAL GLY ARG HIS SER ARG LYS PRO TRP LEU LYS PHE SEQRES 24 A 352 MET ASN ALA ASP ASN GLN HIS LEU VAL SER PRO GLU ALA SEQRES 25 A 352 ILE ASP PHE LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SEQRES 26 A 352 GLU ARG LEU THR ALA LEU GLU ALA MET THR HIS PRO TYR SEQRES 27 A 352 PHE GLN GLN VAL ARG ALA ALA GLU ASN SER ARG THR ARG SEQRES 28 A 352 ALA MODRES 3BE9 CSO A 89 CYS S-HYDROXYCYSTEINE HET CSO A 89 7 HET P04 A 501 27 HETNAM CSO S-HYDROXYCYSTEINE HETNAM P04 19-(CYCLOPROPYLAMINO)-4,6,7,15-TETRAHYDRO-5H-16,1- HETNAM 2 P04 (AZENOMETHENO)-10,14-(METHENO)PYRAZOLO[4,3-O][1,3, HETNAM 3 P04 9]TRIAZACYCLOHEXADECIN-8(9H)-ONE FORMUL 1 CSO C3 H7 N O3 S FORMUL 2 P04 C19 H21 N7 O FORMUL 3 HOH *246(H2 O) HELIX 1 1 ASP A 14 ARG A 19 1 6 HELIX 2 2 PRO A 20 ASP A 25 1 6 HELIX 3 3 TYR A 26 LEU A 29 5 4 HELIX 4 4 GLU A 35 ASP A 37 5 3 HELIX 5 5 LYS A 74 CSO A 89 1 16 HELIX 6 6 ASP A 120 TYR A 125 1 6 HELIX 7 7 PRO A 126 LEU A 128 5 3 HELIX 8 8 THR A 129 GLN A 150 1 22 HELIX 9 9 LYS A 158 HIS A 160 5 3 HELIX 10 10 GLY A 199 VAL A 204 1 6 HELIX 11 11 TYR A 211 ARG A 228 1 18 HELIX 12 12 ASP A 237 GLY A 250 1 14 HELIX 13 13 GLY A 250 TYR A 261 1 12 HELIX 14 14 ASP A 266 GLY A 274 1 9 HELIX 15 15 PRO A 280 MET A 285 5 6 HELIX 16 16 ASN A 289 VAL A 293 5 5 HELIX 17 17 SER A 294 LYS A 303 1 10 HELIX 18 18 ASP A 308 ARG A 312 5 5 HELIX 19 19 THR A 314 HIS A 321 1 8 HELIX 20 20 PHE A 324 ASN A 332 1 9 SHEET 1 A 5 TYR A 39 GLY A 48 0 SHEET 2 A 5 SER A 51 ASN A 58 -1 O GLU A 55 N ARG A 43 SHEET 3 A 5 GLU A 63 LEU A 70 -1 O CYS A 65 N GLY A 56 SHEET 4 A 5 PRO A 109 PHE A 113 -1 O PHE A 113 N ILE A 66 SHEET 5 A 5 LEU A 97 ARG A 102 -1 N LEU A 98 O ILE A 112 SHEET 1 B 2 ILE A 152 MET A 153 0 SHEET 2 B 2 GLU A 180 PHE A 181 -1 O GLU A 180 N MET A 153 SHEET 1 C 2 VAL A 162 ASP A 165 0 SHEET 2 C 2 LYS A 170 LEU A 173 -1 O LYS A 170 N ASP A 165 LINK C LEU A 88 N CSO A 89 1555 1555 1.33 LINK C CSO A 89 N GLY A 90 1555 1555 1.33 CISPEP 1 GLU A 230 PRO A 231 0 -0.45 SITE 1 AC1 10 ARG A 47 ILE A 66 LYS A 68 PHE A 113 SITE 2 AC1 10 GLU A 114 TYR A 115 MET A 163 ILE A 174 SITE 3 AC1 10 ASP A 175 HOH A 572 CRYST1 143.327 59.578 44.835 90.00 103.42 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.006977 0.000000 0.001665 0.00000 SCALE2 0.000000 0.016785 0.000000 0.00000 SCALE3 0.000000 0.000000 0.022930 0.00000